Integrable semi-discretization of the massive Thirring system in laboratory coordinates

Several integrable semi-discretizations are known in the literature for the massive Thirring system in characteristic coordinates. We present for the first time an integrable semi-discretization of the massive Thirring system in laboratory coordinates. Our approach relies on the relation between the continuous massive Thirring system and the Ablowitz-Ladik lattice. The Backlund transformation for solutions to the Ablowitz-Ladik lattice and the time evolution of the massive Thirring system in laboratory coordinates are combined together in the derivation of the Lax system for the integrable semi-discretization of the massive Thirring system.Comment: 10 pages, 0 figure

HCV/HTLV coinfection: Does HTLV-1 interfere in the natural history of HCV-related diseases?

Edgard Marcelino de Carvalho Filho. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. "Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento".Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2017-04-07T12:51:56Z No. of bitstreams: 1 Silva MC HCV HTLV coinfection....pdf: 116203 bytes, checksum: 24e464dc01689486d0e327d8242ac287 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2017-04-07T13:05:39Z (GMT) No. of bitstreams: 1 Silva MC HCV HTLV coinfection....pdf: 116203 bytes, checksum: 24e464dc01689486d0e327d8242ac287 (MD5)Made available in DSpace on 2017-04-07T13:05:39Z (GMT). No. of bitstreams: 1 Silva MC HCV HTLV coinfection....pdf: 116203 bytes, checksum: 24e464dc01689486d0e327d8242ac287 (MD5) Previous issue date: 2016CNPq (Universal); Grant sponsor: LIA ProjectFederal University of Bahia. Department of Hepatology. Salvador, BA, BrazilFederal University of Bahia. Department of Hepatology. Salvador, BA, BrazilFederal University of Bahia. Department of Hepatology. Salvador, BA, BrazilFederal University of Bahia. Clinical and Toxicological Analysis. Salvador, BA, BrazilFederal University of Bahia. Immunology Laboratory of the Health Science Institute. Salvador, BA, BrazilFederal University of Bahia. Immunology Service of the University Hospital Professor Edgar Santos. Salvador, BA, BrazilFederal University of Bahia. Hepatology Center of the University Hospital Professor Edgar Santos. Salvador, BA, BrazilFederal University of Bahia. Hepatology Center of the University Hospital Professor Edgar Santos. Salvador, BA, BrazilHepatitis C virus (HCV) and human T-lymphotropic virus type 1 (HTLV-1) coinfection occurs in many regions. However, few studies have focused on the natural history of HCV-induced liver disease in coinfected patients. To describe the clinical, epidemiological, and histopathological aspects of HTLV-1/HCV coinfection in Brazil. A cross-sectional study with 23 patients coinfected with HCV/HTLV. The control groups consisted of 21 patients monoinfected with HCV and 20 patients monoinfected with HTLV-1. The cytokine profiles (Th1 and Th2 cell responses), clinical, laboratory features, and histopathological aspects were examined. The control group for cytokine analysis validation consisted of patients monoinfected with HTLV, and a fourth group consisted of healthy blood donors. No anthropometric differences present between the three infected groups. We observed higher serum concentrations of IFN-γ in patients coinfected with HCV/HTLV-1 than those in HCV monoinfected patients. The HCV/HTLV-1 coinfected group also exhibited a higher degree of liver steatosis than the HCV monoinfected patients. Results suggest that HCV/HTLV-1 coinfection may result in a different pattern of HCV infection due to the immunologic disorders likely associated with HTLV-1, but there is no clear evidence of the HTLV role in the natural history of HCV infection

GAMMA GLUTAMYLTRANSFERASE IMPACT IN THERAPEUTIC RESPONSE OF CHRONIC HEPATITIS C: a systematic review of the literature

BackgroundThe standard treatment of chronic hepatitis C is the administration of pegylated interferon α2a or α2b in combination with ribavirin, but adverse effects can be observed, as well as the high cost of this therapy. Therefore, there is interest in understanding the predictors of sustained virologic response, as the gamma glutamyltransferase.ObjectiveTo evaluate the serum levels of gamma glutamyltransferase as a predictor of response to treatment with pegylated interferon α and ribavirin in chronic hepatitis C.MethodsThis is a systematic review of literature, conducted by consulting PUBMED, LILACS, MEDLINE, SCOPUS, Cochrane electronic databases, and active search of articles selected between January 2000 and April 2013.ResultsA total of 4,785 titles were iden tified. Out of those material, following inclusion and exclusion criteria, 273 abstracts were selected, by two independent researchers. After reading those texts, the reviewers consensually included ten studies for systematization and classification, according to the criteria of the Oxford Scale. 1B studies are predominant (prospective cohort study - six studies). Rapid virologic response and early virological response were considered as estimates for the sustained virological response. The frequency of virologic response was identified in three studies and early virological response in two, with a total of 392 and 413 patients, respectively; sustained virologic response was reported in nine articles corresponding to 3,787 patients (76.5 %).ConclusionGamma glutamyltransferase is a predictor of sustained virologic response in the treatment of chronic hepatitis C with pegylated interferon α2a or α2b associated with ribavirin

Encefalopatia hepática: relatório da 1º reunião monotemática da Sociedade Brasileira de Hepatologia

Hepatic encephalopathy (HE) is a functional disorder of the central nervous system (CNS) associated with liver failure, either end-stage chronic liver disease or fulminant hepatic failure. Its pathogenesis remains complex and poorly understood. In view of recent advances in the management of HE, the Brazilian Society of Hepatology endorsed a monothematic meeting regarding HE in order to gather experts in the field to discuss related data and to draw evidence-based recommendations concerning: management of HE and intracranial hypertension in FHF, treatment of episodic HE in cirrhosis, controversies in the management of EH including difficult to treat cases and diagnostic and treatment challenges for minimal HE. The purpose of this review is to summarize the lectures and recommendations made by the panel of experts of the Brazilian Society of Hepatology.A encefalopatia hepática (EH) é um distúrbio funcional do sistema nervoso central (SNC) associado à insuficiência hepática, de fisiopatologia multifatorial e complexa. Devido aos avanços no conhecimento sobre o manejo da EH na cirrose e na insuficiência hepática aguda (IHA), a diretoria da Sociedade Brasileira de Hepatologia (SBH) promoveu uma reunião monotemática acerca da fisiopatologia, diagnóstico e tratamento da EH, abordando aspectos controversos relacionados ao tema. Com a utilização de sistemática da medicina baseada em evidências, foram abordados o manejo da EH e da hipertensão intracraniana na IHA, o manejo da EH episódica na cirrose, as controvérsias no manejo da EH e a abordagem da EH mínima. O objetivo desta revisão é resumir os principais tópicos discutidos na reunião monotemática e apresentar recomendações sobre o manejo da síndrome votadas pelo painel de expertos da SBH

Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil

Introduction and objectives: Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir (SIM) and ombitasvir, paritaprevir and dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims of this study were to assess effectiveness and safety of HCV treatment with DAA in real-life world in a highly admixed population from Brazil. Materials and methods: All Brazilian reference centers for HCV treatment were invited to take part in a web-based registry, prospectively conducted by the Brazilian Society of Hepatology, to assess outcomes of HCV treatment in Brazil with DAAs. Data to be collected included demographics, disease severity and comorbidities, genotype (GT), viral load, DAA regimens, treatment side effects and sustained virological response (SVR). Results: 3939 patients (60% males, mean age 58 ± 10 years) throughout the country were evaluated. Most had advanced fibrosis or cirrhosis, GT1 and were treated with SOF/DCV or SOF/SIM. Overall SVR rates were higher than 95%. Subjects with decompensated cirrhosis, GT2 and GT3 have lower SVR rates of 85%, 90% and 91%, respectively. Cirrhosis and decompensated cirrhosis in GT1 and male sex and decompensated cirrhosis in GT3 were significantly associated with no SVR. Adverse events (AD) and serious AD occurred in 18% and 5% of those subjects, respectively, but less than 1% of patients required treatment discontinuation. Conclusion: SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries